<DOC>
	<DOCNO>NCT00111449</DOCNO>
	<brief_summary>The purpose study determine effect etanercept 50 mg twice weekly compare placebo 12 week psoriasis area severity index ( PASI ) subject psoriasis . This study also evaluate safety tolerability etanercept 50 mg twice weekly ; determine effect etanercept 50 mg twice weekly patient report outcome ( PRO ) ; characterize pharmacokinetics ( PK ) profile etanercept 50 mg twice weekly .</brief_summary>
	<brief_title>Evaluating Safety Etanercept 50 mg Twice Weekly Subjects With Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Active , clinically stable , plaque psoriasis involve great equal 10 % body surface area A minimum PASI score 10 obtained screen period Active guttate , erythrodermic , pustular psoriasis time screen visit Evidence skin condition time screen visit ( e.g. , eczema ) would interfere evaluation effect investigational product psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Psoriasis , adult</keyword>
	<keyword>skin , Phase 3</keyword>
	<keyword>clinical trial , Amgen</keyword>
	<keyword>etanercept , EnbrelÂ®</keyword>
	<keyword>moderate , severe</keyword>
</DOC>